Regado Biosciences Inc (RGDO) 1.21 $RGDO Venous (Vein)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regado Biosciences Inc (RGDO) 1.21 $RGDO

Venous (Vein) Thrombosis - Pipeline Review, H1 2015 Report Gives Vital Latest News and Deals
M2 - Mon Jun 08, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjcg3h/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H1 2015" report to their offering. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/rj...enous_vein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMY: 72.31 (+1.06), RGDO: 1.21 (unch)

Global Venous Thromboembolism Therapeutics Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3cbpk/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - GlycoMimetics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - edoxaban tosylate - Gammarin - GCC-2107 - GMI-1271 - ISIS-FXIRx - Lysimab - REG-2 - rivaroxaban - semuloparin For more information visit http://www.researchandmarkets.com/research/z3cbpk/venous
PTLA: 23.84 (+0.03), ISIS: 57.56 (-0.28), GLYC: 6.24 (-0.08), RGDO: 1.21 (unch)

Tobira Therapeutics Completes Financing and Merger with Regado Biosciences
PR Newswire - Mon May 04, 3:30PM CDT
Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, announced today the completion of its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, through May 4). In conjunction with the closing of the merger, Tobira raised $40 million of common stock from a combination of new investors and all current Tobira institutional investors, including the previously announced $13 million in debt that converted to common stock in this closing. Together with approximately $33 million net cash on Regado's balance sheet, the combined company has approximately $70 million in cash to advance clinical development of first-in-class dual CCR2/CCR5 inhibitor cenicriviroc (CVC), which is being evaluated in the Phase 2b CENTAUR clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.
TBRA: 12.00 (+0.34), RGDO: 1.21 (unch)

Tobira Therapeutics Highlights Presentations at The International Liver Congress 2015
PR Newswire - Wed Apr 08, 7:00AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today presentations of new data for cenicriviroc (CVC) at "The International Liver Congress," a conference organized by the European Association for the Study of the Liver (EASL). The conference is being held April 22-26 in Vienna, Austria.
TBRA: 12.00 (+0.34), RGDO: 1.21 (unch)

Tobira Therapeutics Highlights Presentations at the AASLD's Industry Colloquium for Novel Targets and Therapies in Liver Disease
PR Newswire - Fri Mar 20, 6:30AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it will be presenting at the "Industry Colloquium: Novel Targets and Therapies in Liver Disease" a conference organized by the American Association for the Study of Liver Disease (AASLD). The conference is being held today and tomorrow, March 21st, in Durham, NC.
TBRA: 12.00 (+0.34), RGDO: 1.21 (unch)

Tobira Therapeutics completes USD13m financing in support of development of CVC in non-alcoholic steatohepatitis
M2 - Tue Mar 10, 6:08AM CDT
Biopharmaceutical company Tobira Therapeutics revealed on Monday that it has completed a USD13m convertible note financing.
TBRA: 12.00 (+0.34), RGDO: 1.21 (unch)

Regado Biosciences (RGDO) Jumps: Stock Surges 20.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 8:11AM CDT
Regado Biosciences, Inc. (RGDO) was a big mover last session, as the company saw its shares rise over 20% on the day.
ANIP: 52.79 (+1.43), RGDO: 1.21 (unch)

Tobira Therapeutics Closes Financing to Support Development of CVC in Non-Alcoholic Steatohepatitis
PR Newswire - Mon Mar 09, 7:00AM CDT
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it has completed a $13 million convertible note financing. The funding will support Tobira's clinical program with cenicriviroc (CVC), its dual CCR2/CCR5 inhibitor targeting immuno-inflammation and fibrogenesis in non-alcoholic steatohepatitis (NASH), a disease associated with obesity and diabetes that often leads to liver cirrhosis. Abingworth LLP, Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. and Stonepine Capital Management LLC, in addition to all of Tobira's current investors, participated in the financing. Financial terms are not being disclosed at this time. The closing of the note financing and the investment by Tobira's current investors was contemplated by the previously announced merger agreement with Regado Biosciences. The merger is expected to close in the second quarter of 2015.
TBRA: 12.00 (+0.34), RGDO: 1.21 (unch)

Thromboembolism Therapeutics Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Mar 03, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66bfv/thromboembolism) has announced the addition of the "Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Cereno Scientific AB - CSL Limited - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - C-3 - CSL-3F7 - edoxaban tosylate - Gammarin - GCC-2107 - ISIS-FXIRx - Lysimab - Protein for Thromboembolism and Blood Coagulation - REG-2 - rivaroxaban - semuloparin - Small Molecules to Inhibit HDAC for Thromboembolism - TAP-ANV - YG-001 For more information visit http://www.researchandmarkets.com/research/s6...boembolism
PTLA: 23.84 (+0.03), ISIS: 57.56 (-0.28), RGDO: 1.21 (unch)

Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 4.95 (+0.06), GILD: 82.45 (+0.66), PSTI: 1.35 (+0.14), MRK: 57.04 (+0.79), AZN: 28.70 (+0.06), EGRX: 38.30 (-1.00), BMY: 72.31 (+1.06), RGDO: 1.21 (unch)

Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 3:54PM CST
Intercept Pharmaceuticals, Inc.'s (ICPT) obeticholic acid (OCA) received Breakthrough Therapy designation from the FDA for nonalcoholic steatohepatitis (NASH).
MNK: 56.68 (+0.15), ICPT: 148.10 (+6.01), RGDO: 1.21 (unch), CELG: 99.23 (+2.37)

SurModics Beats on Q1 Earnings, Reaffirms 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 9:20AM CST
SurModics, Inc.'s first-quarter fiscal 2015 (ended Dec 31, 2014) adjusted earnings of 25 cents per share beat the Zacks Consensus Estimate by 4 cents.
SRDX: 23.35 (+0.16), AMAG: 24.46 (+0.83), RGDO: 1.21 (unch), CELG: 99.23 (+2.37)

Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:20PM CST
Alexion Pharmaceuticals' (ALXN) fourth-quarter 2014 earnings (including stock-based compensation expense) of $1.15 per share.
ALXN: 121.41 (-2.73), AMAG: 24.46 (+0.83), RGDO: 1.21 (unch), CELG: 99.23 (+2.37)

BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 2.33 (-0.11), OPHT: 54.16 (-0.34), RGDO: 1.21 (unch), CELG: 99.23 (+2.37)

Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 9:51AM CST
Celgene Corporation (CELG) reported fourth-quarter 2014 earnings of 88 cents per share.
ALXN: 121.41 (-2.73), AMAG: 24.46 (+0.83), RGDO: 1.21 (unch), CELG: 99.23 (+2.37)

Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 82.18 (+0.96), GEVA: 238.60 (+2.80), RGDO: 1.21 (unch), CELG: 99.23 (+2.37)

Strength Seen in ZIOPHARM (ZIOP): Stock Rises 11.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 8:25AM CST
ZIOPHARM (ZIOP) was a big mover last session, with its shares rising roughly 12% on the day.
ZIOP: 5.85 (-0.07), RGDO: 1.21 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 61

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 455

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Shaquille O'Neal Empowers Young Leaders with New Scholarship

Updated Category News Views 743

Shaquille O'Neal Champions the Future of Entrepreneurship Full scholarships, elite mentorship, and real-world learning experiences are now within reach for aspiring creators and entrepreneurs, thanks to a groundbreaking initiative launched by Campus, a modern two-year college committed to nurturing the next generation of leaders. This new scholarship program, backed by...

Continue Reading
Investors Take Action: Class Action Lawsuits on the Rise

Updated Category News Views 146

Protecting Your Investments: Class Action Overview Investing in public companies often comes with risks, and sometimes those risks manifest as legal issues. Recently, class action lawsuits have sprung up involving several well-known companies. These lawsuits present opportunities for investors to raise their voices against corporate misconduct and reclaim lost...

Continue Reading
Top Strategies from DealerFire to Enhance Website Engagement

Updated Category News Views 171

Effective Strategies to Reduce Dealership Website Bounce Rates Transforming website visitors into clients is essential for dealerships, and DealerFire offers insightful strategies to enhance website performance effectively. Boosting Page Load Speed The Importance of Speed Website speed plays a critical role in keeping visitors on the site. DealerFire stresses the need to...

Continue Reading
Lassila & Tikanoja's Annual General Meeting Announcement

Updated Category News Views 115

Notice of the Annual General Meeting Lassila & Tikanoja plc has issued a notice regarding the upcoming Annual General Meeting. This meeting serves as an important gathering for shareholders to discuss significant matters concerning the company's future. Meeting Details The Annual General Meeting will take place on Thursday, March 27, 2025, at 4:00 PM, with registration...

Continue Reading
Soapy Joe's Expands Its Reach with 25th Car Wash Location

Updated Category News Views 490

Soapy Joe's Expands Its Reach with 25th Car Wash Location Soapy Joe's Car Wash, a family-owned favorite in the San Diego area, is thrilled to announce the arrival of its 25th location in the community. This new car wash is positioned to provide not only top-notch car cleaning services but also a unique, enjoyable experience for local residents. Grand Opening Celebration...

Continue Reading